Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Transcription

Volumn 2, Issue 5, 2011, Pages 207-210

  Knappskog, Stian ^a,b   Lønning, Per E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Endometrial cancer; MDM2; Ovarian cancer; Polymorphism

Indexed keywords

TRANSCRIPTION FACTOR SP1; MDM2 PROTEIN, HUMAN; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER RISK; COLORECTAL CANCER; ETHNICITY; GENE AMPLIFICATION; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LARGE CELL LYMPHOMA; MDM2 GENE; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE; PHYLOGENY; PROMOTER REGION; PROTEIN BINDING; SINGLE NUCLEOTIDE POLYMORPHISM; SOFT TISSUE SARCOMA; SURFACE PLASMON RESONANCE; TRANSCRIPTION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW; RISK FACTOR;

HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053018982     PISSN: 21541264     EISSN: 21541272     Source Type: Journal    
DOI: 10.4161/trns.2.5.16813     Document Type: Article

References (26)

1. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9; DOI: 10.1038/387296a0.
2. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420:25-7
3. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303; DOI: 10.1038/387299a0.
4. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378:206-8.
5. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378:203-6.
6. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, et al. Interaction between the retinoblastoma protein and^the oncoprotein MDM2. Nature 1995; 375:694-8.
7. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/ DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375:691-4; DOI: 10.1038/375691a0.
8. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-3; DOI: 10.1038/358080a0.
9. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453-9; DOI: gkb548 [pii].
10. Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Research 1997; 57:3562-8.
11. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Research 1993; 53:3226-8.
12. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003; 3:145-60.
13. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 2010; 18:147-59.
14. Inuzuka H, Fukushima H, Shaik S, Wei W.Novel insights into the molecular mechanisms governing mdm2 ubiquitination and destruction. Oncotarget 2010; 1:685-90.
15. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000; 242:15-29.
16. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers and implications for chemotherapy. Curr Cancer Drug Targets 2005; 5:27-41.
17. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
18. Bond GL, Menin C, Bertorelle R, Alhorpuro P, Aaltonen LA, Levine AJ. MDM2 SNP30 9 Accelerates colorectal tumour formation in women. J Med Genet 2006; 43(12):950-2.
19. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Research 2006; 66:5104-10.
20. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010; 18:220-30.
21. Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 2010; 120:211-6; DOI: 10.1007/ s1 05 49-00 9-0467-1.
22. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case- control studies. Cancer Epidemiol Biomarkers Prev 2007; 16:2717-23.
23. Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, et al. The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell 2011; 19:273-82.
24. Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Hveem K, et al. Impact of the MDM2 promoter polymorphsims SNP285 and SNP309 on endometrial cancer risk among Caucasians. ASCO 2011; 5092.
25. Smirnov DA, Cheung VG. ATM gene mutations result in both recessive and dominant expression phe-notypes of genes and microRNAs. Am J Hum Genet 2008; 83:243-53.
26. Knappskog S, Lonning PE. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget 2011; 2:251-8.